zilongwang/ReadingBank huggingface dataset:
Meningitis ACWY or B: Tick-borne Encephalitis: Japanese Encephalitis: Other: Medical Student Declaration I certify that the travel arrangements for which I am requesting travel advice and vaccination has approval by my Head of Department or my Departmental Central Administrator. N.B. This travel relates solely to journey(s) to be taken on official University of Oxford business. Signed: Date: The information collected on this form is processed in accordance with the principles of the Data Protection Act 1998. All information you provide is held securely in confidence as part of your medical record by the Occupational Health Service
Medical Terminology Cardiovascular Disease angi/o arteri/o brad/y—slow cardi/o cereb/o cor—heart cyan/o—blue gram/o hemangl/o my/o—muscle orrhex’s phleb/o scler/o—hard tach/y—fast thromb/o—clot vas/o varix—swollen vein vena—vein xanta/o—yellow C.V. Diagnostic Terms aneurysm arteriosclerosis atheroma atherosclerosis cardiac arrest cardiac cachexia cardiomegaly cerebrovascular accident (CVA) congestive heart failure coronary heart disease (CHD) dyslipidemia embolism fatty streaks homocysteine hypercholesterolemia
C.V. Chart Abbreviations CABG AHA AI ASHD atr AV BP brady BV CAD cardio CBC CCCR CCU CHD CHF Chol CP CPR CVA ECG, EKG FFA fib HCVD HTN, HPN MI MS MVR HTG OHS PA PT RHD SOB tach TG Throm vent
I realise I have confused generations of South Birmingham aspiring GPs with my insistence on the only certainty I know – uncertainty. Can you help me? P.S Have you the one about Heidegger and Schrodinger driving down a road together? P.P.S -Seriously! Richard Lehman has recently written a series in JAMA “Understanding the stepwise diagnostic process and developing effective diagnostic skills lie at the heart of medical education. Making a diagnosis is often uncertain and ambiguous; diagnostic tests have limitations and, if used improperly, can be misleading. For clinicians, thoroughly understanding each step can help them look critically at their own practice, hone their skills, improve their performance, and involve patients and families in the process.” It’s worth a look! It starts here, Workshop on Weaving wisdom into VTS, helping trainees deal with uncertainty Dr Julian Treadwell Julian Treadwell is a GP in Wiltshire who became involved in the Preventing Overdiagnosis/Too Much Medicine movement a few years ago having become gradually more concerned about the size of his repeat prescription pile and how much time he was spending dealing with what felt like low value and sometimes harmful medical interventions. He established the RCGP Standing Group on Overdiagnosis with Dr. Margaret McCartney in 2014 and further exploration in this field has led to work with NICE and other organisations. He currently has a half time NIHR In-Practice Fellowship at the Dept of Primary Health Care Sciences in Oxford where he is looking at guidelines and shared decision making. Julian will be present an introductory keynote lecture about Overdiagnosis, which will most certainly reveal a need for more medical wisdom. Dr Steve Walter assumes many positions which include Head of School of Postgraduate General Practice, Health Education West Midlands. Honorary Senior Lecturer in Primary Care, University of Worcester. GP partner in Studley, South Warwickshire.
Yamhill Health Net Life Insurance Company Health Net Violet 2 (PPO) 014 PPO No Enhanced Alternative $0.00 $24.00 $0.00 Yamhill Health Net Health Plan of Oregon, Inc. Health Net Ruby (HMO) H6815 003 HMO No Enhanced Alternative $0.00 $0.00 $0.00 Yamhill Kaiser Permanente Kaiser Permanente Senior Advantage (HMO) H9003 001 HMO No Enhanced Alternative $73.40 $39.50 $19.80 Yamhill Kaiser Permanente Kaiser Permanente Senior Advantage (HMO) H9003 006 HMO No Enhanced Alternative $15.40 $28.60 $0.00 Yamhill Providence Health Assurance Providence Medicare Extra + RX (HMO) H9047 001 HMO No Enhanced Alternative $123.40 $49.60 $15.80 Yamhill Providence Health Assurance Providence Medicare Choice + RX H9047 024 HMOPOS No Enhanced Alternative $41.60 $46.40 $12.60 Yamhill Aetna Medicare Aetna Medicare Choice Plan (PPO) H9431 005 Local PPO No Enhanced Alternative $3.80 $13.20 $0.00 Yamhill Aetna Medicare Medicare Select Plan (PPO) H9431 008 Local PPO No Enhanced Alternative $33.10 $13.90 $0.00
practices young adult pts with metabolic disorders. This would be done though consultation with Dr. Mark Korson and the Genetic Metabolic Center for Education (GMCE). GMCE is a new entity designed to support specialists who don’t have expertise in metabolics. Monica wondered if the model might work with family physicians as well. Dr. Korson and his business manager are happy to talk with our group, and the group agreed that they would like to hear more about this proposal. Karen will contact Mark and ask him and his business manager to be on our next call. Ardis (who joined the call at 9:15) will formulate some specific questions to ask Mark re: how the pilot project would work. Monthly NCC Care Coordination Workgroup calls At the NIPN meeting Greg talked with Chuck Norlin (the chair for these calls). We decided to suggest a project to document the efficacy of having care coordinators in practices. Suggested outcome questions to answer for practices who have care coordinators: Do children with complex conditions miss fewer days of school? Do parents of children with complex conditions miss fewer days of work? Do children with complex conditions have fewer hospitalizations and/or ER visits Meeting Planning and Hygiene Please identify yourself before you speak. Dealing with silence: On future calls, Greg may go “round the room” to ask attendees about their opinions; each attendee can “pass” if they have nothing to share Length of some calls may only need to be 30 minutes. TIME CHANGE FOR FUTURE MEETINGS: After Marinell, Kathy, Tara, and Alex left the call, Ardis and Amy signed on. The consensus was that calls will continue to occur the second Thursday of the month. New start time will be 9:15 am which seems to work better for most people. Other issues discussed Either Marinell or Cathy (Greg cannot remember who suggested this) will email Greg the address of Reba Porter, who is involved in a multistate study addressing family satisfaction with service delivery. Doing a project involving Family Voices and their involvement with families who have children with complex genetic and metabolic conditions. Tara shared that all states have a Family Voices group. To Do
GIE (if not used $20 - $0 Remainder $850 Earned Income Exclusion (EIE) $65 - $65 Remainder $785 Impairment Related Work Expense (IRWE) (16% of wages or actual amount if higher) - $0 Remainder $785 Divide by 2 $392.50 Work Expenses (BWE) (25% of gross wages or actual amount if higher) - $0 Total Countable Earned Income = $392.50 Countable Unearned Income $1,000 Total Countable Earned Income + $392.50 PASS Deduction - $0 Countable Income = $1,392.50 Tom’s countable income, $1,392.50, will be over 135% of the FPL ($1,324 in 2015), which means he would not be eligible for Full LIS. But, his income does fall below 150% of the FPL ($1,471 in 2015), which means he would likely be eligible for Partial LIS. To support Tom in pursuing his work goal, it will be important for him to know his options. He will be able to use Partial LIS instead of Full LIS or (if Medicaid eligibility is an option for Tom in his state) he will be able to maintain Full LIS by enrolling in Medicaid. Reporting Income and Resource Changes and LIS Redeterminations To determine subsidy eligibility and whether the individual qualifies for a full or partial subsidy, Social Security considers all of the countable income the individual and living-with spouse receive (or expect to receive) for a period of 12 months. Although the computation of income for subsidy eligibility is based on income projected for 12 months, the computation is not linked to a particular calendar year. The subsidy determination system uses the 12-month projection of income because the Federal Poverty Limit (FPL) income limits are issued as annual income limits. At the point when an individual files for subsidy, the 12-month projection of income is compared to the current year’s FPL income limit. If the individual’s projected income is under
Include only prescriptions that may require reimbursement. Claim 1 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, cream, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $ 2 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, cream, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $ Claim 3 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, cream, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $ Claim 4 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $ Claim 5 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, cream, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $ Claim 6 (please print) Drug Name NDC # (on receipt or call pharmacy) Prescription # Date of Fill Dosage (25 mg, etc) Quantity Prescriber’s Name (Doctor) Days Supply Form (capsules, etc) Total Charge $ Amt Primary Paid $ Amt You Paid $
In this sample, the resident appears to have no remaining Medicare A days as indicated by the 0 in both the SNF Full Days and SNF Co Days. HOWEVER, notice the date of last billing! Medicare had not been billed for this resident since 2007. At this point, the facility needs to verify that the resident has had at least 60 Wellness Days since the last time on Medicare, and then proceed to examine the resident’s history over the last 90 days (at least) to determine which day of Medicare we might be starting on. Once Medicare is billed again, the system will reset showing the new benefit period and available days. Sample 3 The screening indicates an effective date for Part B benefits. Benefits are then shown for Physical Therapy and Speech, which are lumped together in one category, and for Occupational Therapy. For Medicare Part B, the amount shown in the blanks is the amount of therapy dollars billed for the resident as of January 1st 2013. When you see a screening with $0.00 amounts shown, it means that no therapy dollars have been billed to Medicare. However, this only indicates the billing that has been processed – there could still be billing out there that is not reflected here! Sample 4 This screening sample indicates that the resident had $291.69 worth of physical therapy and/or speech therapy charges billed to Medicare B during the year, and $130.29 worth of occupational therapy billed during the year. Therapy will want to review these amounts frequently to monitor when the resident reaches the “Therapy Cap” at $1920 and when a resident would reach the “Therapy Threshold” of $3700 for the year. At times we do have reason to bill therapy past the
During the past four weeks, how much bodily pain have you had?  No pain.  Mild pain.  Moderate pain.  Severe pain. Do you exercise for about 20 minutes three or more days a week?  Never.  Sometimes.  Frequently.  Always. Do you always fasten your seat belt when you are in a car?  Yes.  No. Have you fallen two or more times in the past year?  Yes.  No. Are you afraid of falling?  Yes.  No. Have you been given any information to help you with the following: Hazards in your house that might hurt you?  Yes.  No. Keeping track of your medications?  Yes.  No. Because of any health problems, do you need the help of another person with your personal care needs such as eating, bathing, dressing, or getting around the house?  Yes.  No. Can you get to places out of walking distance without help? (For example, can you travel alone on buses, taxis, or drive your own car?)  Yes.  No. Are you having driving your car?  Yes.  No.  Not applicable, I do not use a car. Can you go shopping for groceries or clothes without someone’s help?  Yes.  No. Can you do your housework without help?  Yes.  No. Can you prepare your own meals?  Yes.  No. How often do you have trouble taking medicines the way you have been told to take them?  Never.  Sometimes.  Frequently.  Always. Can you handle your own money without help?  Yes.  No.
HEARING HANDICAP INVENTORY FOR THE ELDERLY SCREENING (HHIE-S) NAME: DOB: DATE: YES NO 1. Are you having hearing problems? Instructions: If you respond YES then please answer the further follow-up questions below. YES (4 points) SOMETIMES (2 points) NO (0 points) 1. Does a hearing problem cause you to feel embarrassed when meeting new people? 4 2 0 2. Does a hearing problem cause you to feel frustrated when talking to members of your family? 4 2 0 3. Do you have difficulty hearing when someone speaks in a whisper? 4 2 0 4. Do you feel handicapped by a hearing problem? 4 2 0 5. Does a hearing problem cause you difficulty when visiting friends, relatives, or neighbors? 4 2 0 6. Does a hearing problem cause you to attend religious services less often than you would like? 4 2 0 7. Does a hearing problem cause you to have arguments with family members? 4 2 0 8. Does a hearing problem cause you difficulty when listening to TV or radio? 4 2 0 9. Do you feel that any difficulty with your hearing limits or hampers your personal or social life? 4 2 0 10. Does a hearing problem cause you difficulty when in a restaurant with relatives or friends? 4 2 0 Add column answers together = TOTAL: _____________ Interpretation of Score: 0-8 suggests no hearing handicap 10-24 suggests mild-moderate hearing handicap, consider referral 16-40 suggests significant hearing handicap, consider referral
Determination Meets standards – no further action Meets standards with minor changes Meets standards with major changes Fails to meet Recommendations / Actions Deadline for action Name of Assessor Role Date Appendix 3 Example of South Ayrshire Council Internal Incident Report Form SOUTH AYRSHIRE COUNCIL INTERNAL INCIDENT REPORT FORM OFFICE USE ONLY Code: Investigation Date: To be completed in accordance with SAC Incident Reporting & Investigation Standard for all work-related incidents occurring within Council controlled property, involving Council employees, persons the supervision of the Council, contractors or other members of the public. Complete all sections in CAPITALS and in black ink. Send the completed original AR1 Form to Corporate Safety Team and retain a copy for your own records. DIRECTORATE: SERVICE: REF: A - INJURED PERSON’S DETAILS (if relevant) Full Name: Work Base: Home Address: Address: Postcode: Tel: Occupation: Date of Age: SEX: M F Status: Council Employee Member of Public Employee under18 Contractor Client/Pupil Other
Partners data and research In assessing the impact set out above what evidence has been provided by partners. Please specify partners Examples of other Local Authorities approach to medication assistance was gathered and assessed. Partner agencies who provide care services across South Ayrshire provided information about existing policies and procedures. Gaps and Uncertainties Have you identified any gaps or uncertainties in your understanding of the issues or impacts that need to be explored further? Medication errors are currently recorded on Incident Report Forms at each and sent to Corporate Health and Safety. The new policy asks Service Managers to send copies of the Incident Report Forms to a dedicated email address, so that a learning log can be established. Section Four: Detailed Action Plan to address identified gaps in: a) evidence and b) to mitigate negative impacts No Action Lead Officer(s) Timescale 1 Ensure that the policy is available in community languages upon request. Frank McMenemy July 2013 2 Ensure that the policy is available in alternative formats (eg Braille) upon request Frank McMenemy July 2013 3 Ensure large print and easy to read copies of this policy are available for service users with visual impairments and learning disabilities Zhan McIntyre July 2013 4 Prepare guidance on providing care to individuals with spiritual or religious beliefs Zhan McIntyre July 2013 Section Five - Performance monitoring and reporting Considering the policy as a including its equality and diversity implications: When is the policy intended to come into effect? Autumn 2013 When will the policy be reviewed? Autumn 2014 Scrutiny Panel will have oversight of the policy? Leadership Panel Section 6 South Ayrshire Council Appendix .......... Summary Equality Impact Assessment Implications & Mitigating Actions Name of Policy: Medication Assistance Policy This policy will assist the Council’s ability to eliminate discrimination; advance equality of opportunity; and foster good relations as follows: Eliminate discrimination Advance equality of opportunity
Company Information – Allergan Patient Assistance Program Company Name Allergan Medication Names Alphagan P, Lumigan, Combigan, Restasis Mailing Address P.O. Box 42847, Cincinnati, OH 45242 Phone 1-800-553-6783 Fax 1-513-618-0054 Website Other Instructions Patient can initiate the application process online Application Information - All applications require the doctor’s signature Send completed application Attach of Income to all applications Mail completed form to CECA: 10431 Patterson Ave, Richmond, VA 23238 The doctor will sign the form We will mail the form back to you to send New applications can be faxed or mailed Application valid for: for 1 year Amount received each order: You will receive a 6 month supply Refill and Renewal Information Renewal application to be done: A Renewal application should be done each year Refills to be done: Re-order when you start your last bottle! Automated Refill options: Not Currently Available Commonwealth Eye Care Contact Information Shauna Shirey, COA Phone: 804-217-6363 Email: shauna@commonwealtheye.com Stacy Wright, COA Phone: 804-217-6363 stacy@commonwealtheye.com
Exam (Z) 60 June Exam consists of three parts: multi choice questions, open questions and prescription tasks. Totally, 100 points may be collected (50, 30, 20). Final number of points is converted to the final mark according to the official scheme of university The final mark calculated according to formula: 20%X+20%Y+60%Z Author Year of No of periodical or vol. of Publication place and publisher or Internet link Required reading Rang H.P. et al. 2012 Pharmacology 7 ed. Churchill Livingstone Katzung B.G. 2004 Bazinė ir klinikinė farmakologija 9 leidimas Charibdė, Lietuva Katzung B.G. 2011 Basic and clinical pharmacology. 11 ed. McGraw Hill Recommended reading J. Gulbinovič , A. Ambrozaitis, A. Marcinkutė 2004 Infekcijos ir priešinfekciniai vaistai. Vaistų žinios, J. Gulbinovič. 2001 Infekcijos ir antimikrobiniai vaistai: Bakterinės infekcijos ir antibakteriniai vaistai Vaistų žinios, 2011 Goodman & Gilman’s The Pharmacological basis of therapeutics 12 ed. McGraw-Hill
Section 3: Medicinal cannabis product details Examples of product information required Name of product (trade name) Formulation Dosage form Route of administration Shelf-life (closed and if applicable) Container type and material Ingredient(s) (including active ingredient(s) and excipient(s)) Concentration or proportion of ingredient(s) per dosage unit Example: XYZ THC/CBD Oral Solution Example: THC CBD Grapeseed oil Example: Each bottle contains: THC:CBD (1:1 ratio) 10mg/ml (THC) 10mg/ml (CBD) To 50 mL Example: Solution Example: Oral Example: 2 years at 2-8°C (closed) 7 days at 25°C Example: glass bottle Example: Smithtrade Indica dried cannabis bud (afghani) Example: THC CBD Example: Each bud contains: 22.4% (THC) <0.1% (CBD) Example: Inhalation Example: Inhaled Example: LDPE bag Example: MED CBD and hemp oil Capsules Example: CBD and hemp oil Example: Each capsule contains: 15mg (CBD) 375mg (hemp oil) Example: Capsule Example: Oral Example: Al/Al blister pack in cardboard box
the medicinal cannabis product details in the table below: Name of product (trade name) Formulation Dosage form Route of administration Shelf-life (closed and if applicable) Container type and material Ingredient(s) (including active ingredient(s) and excipient(s)) Concentration or proportion of ingredient(s) per dosage unit Please attach additional pages if there are more than four medicinal cannabis products.
Renal dialysis units Medical equipment or goods for use of disabled person Resuscitation equipment Medical equipment Resuscitation dummies Resuscitation training Scalpels Medical equipment X Screens Sphygmomanometers Medical equipment Splints Medical equipment X Stationery X Sterilising solutions Stethoscopes Medical equipment Surgical gloves Medical equipment Surgical Medical equipment Surgical masks Medical equipment Suture needles Medical equipment Swabs Medical equipment X Tape recorders X Television sets Test tubes Laboratory equipment Thermometers, clinical Medical equipment Thermometers, other Scientific equipment Tongue depressors Medical equipment X Towels X Uniforms Video cameras equipment Video tapes equipment Video players Video equipment Video monitors Video equipment X Waste disposal bags, boxes, jars and sacks X disposal machinery Weighing machines Scientific equipment Wheelchairs Goods for use of disabled person Wound dressings Medical equipment X-ray films/plates Medical equipment X-ray machines - medical Medical equipment X-ray machines - other Scientific equipment X-ray viewers Medical equipment Further information can be obtained from: HM Customs & Excise website: Notice 700 - The VAT Guide, All sections
What are the security issues/risks? What are the potential consequences or impact? Action(s) required to minimise Responsible person Action by when Actions to be completed for main pharmacy and associated pharmacy stores What are the security issues/risks? What are the potential consequences or impact? Action(s) required to minimise Responsible person Action by when Actions to be completed for wards/departments What are the security issues/risks? What are the potential consequences or impact? Action(s) required to minimise Responsible person Action by when Comments
1 Ideas about the cause of disease and illness ● Continuity and change in explanations of the cause of disease and illness. ● The influence in Britain of Pasteur’s Germ Theory and Koch’s work on microbes. 2 Approaches to prevention and treatment ● The extent of change in care and treatment: improvements in hospital care and the influence of Nightingale. ● The impact of anaesthetics and antiseptics on surgery. ● New approaches to prevention: the development and use of vaccinations and the Public Health Act 1875. 3 Case studies ● Key individual: Jenner and the development of vaccination. ● Fighting Cholera in London, 1854; attempts to prevent its spread; the significance of Snow and the Broad Street pump. c1900–present: Medicine in modern Britain Revised? 1 Ideas about the cause of disease and illness ● the influence of genetic and lifestyle factors on health. ● Improvements in diagnosis: the impact of the availability of tests, scans and monitors. 2 Approaches to prevention and treatment ● The extent of change in care and treatment. The impact of the NHS and science and technology: improved access to care; advances in medicines, including magic bullets and antibiotics; high-tech medical and surgical treatment in hospitals. ● New approaches to prevention: mass vaccinations and government lifestyle campaigns. 3 Case studies ● Key individuals: Fleming, Florey and Chain’s development of penicillin. ● The against lung cancer in the twenty-first century: the use of science and technology in diagnosis and treatment; government action.
IRB#: PI: Submitter: Date Submitted: Note: Numbers in parentheses indicate eIRB section and research summary section. [i.e. (06 & 10) referes to eIRB 06. Research Summary & Abstract and 10. Subject Population Groups and Enrollment.] Division Submitter Y,N,N/A Required elements prior to submission for IRB review Is the funding source cited? (04) Is SPS# entered? (if applicable) (04) If funding is Federal, AHA or March of Dimes, are the entire grant & budget attached? (04) If funding is from private industry, is the sponsor’s protocol attached? (07) If funding is from private industry and involves an investigational drug/device, is the investigational brochure included? (08) Number of subjects in the study population (10) Age of study population (06) Are there exclusions in study population? (06 & 10) Are exclusions justified? If not, why? (06 & 10) Data Use/Transfer Agreement? Duke researchers wishing to transfer or use human subject data must contact ORC to initiate a discussion on the proposed data transfer or use. Material Transfer Agreement (MTA)? An agreement entered into by the parties to govern the provision or receipt of research material. The specific form of agreement depends upon the nature of the material, the intended use, whether the recipient is an academic or commercial organization, and the consideration of any intellectual property interests associated with the material. Potential subject identification & recruitment: --Will a review preparatory to research occur? If not, (13.1) --Is a waiver of HIPAA authorization for records review requested? (13.2) --How subjects will be identified? (06,5) --How subjects will be recruited? (06,6) --Is PHI to be collected justified? (13.1) Plan for protection of subject privacy? (12,06) Plan for protecting confidentiality of PHI &/or specimens? (12, 14) Is a consent form attached? (14) --If not, is a waiver of consent request attached? (13.2) --If a waiver is requested, is it justified? (13.1) If a consent form is attached, are the specific requirements for valid authorization listed below included in the document: --The information --Who may use or disclose the information CRU
April 2018 1 2 First Aid Recertification OSSA Fall Protection (MI Safety) 3 H2S Alive! Confined Level II 4 Emergency/ Standard First Aid Day 1 Hours of Service\Fatigue Management 5 Standard First Aid Day 2 Ground Disturbance Level II 6 First Aid Recertification H2S Air Brakes (7:45) 7 Air Brakes (7:45) Emergency/ Standard First Aid Day 1 8 Standard First Aid Day 2 9 First Aid Recertification Fall Protection (1/2 day) 10 H2S Alive! Aerial Work Platform (prerequisite Fall Protection- can be OSSA certified) 11 Emergency/ Standard First Aid Day 1 OSSA Confined Space 12 Standard First Aid Day 2 ENFORM ODA 13 First Aid Blended Option H2S Skidsteer Training 14 15 16 First Aid Recertification Fall Protection (1/2 day) 17 H2S Load Securement Fire Awareness 18 Emergency/ Standard First Aid Day 1 Confined Level II ENFORM ODA 19 Standard First Aid Day 2 Ground Disturbance Level II ENFORM ODA 20 First Aid Recertification H2S Alive! Air Brakes (7:45) 21 Air Brakes (7:45) Emergency/ Standard First Aid Day 1 Home Alone – 1:00 pm 22 Standard First Aid Day 2 23 First Aid Recertification OSSA Fall Protection (MI Safety) 24 H2S Alive! Live Fire Training 25 Emergency/ Standard First Aid Day 1 26 Standard First Aid Day 2 ENFORM ODA 27 First Aid Recertification H2S Alive! 28 29 30 First Aid Recertification Fall Protection (1/2 day) Looking for labourers or Class 1 drivers? Each month, we have people completing our government funded programs. Contact us for more information on our program or for how we can help you train up a potential new recruit by considering the person for our next funded program. Call for information on Class 1 and Class 3 Training
AY 18 New Resident Orientation Internal Medicine Tuesday, June 13 or June 16, 2017 Computer Class A 90 minute session will be assigned Tuesday, June 13, 2017 Managing Fatigue, Work-Life Balance, and Resilience BSI Conference Room 12:00 p.m. – 1:00 p.m. Wednesday, June 14, 2017 ACLS Part 1 IS Training Room 3 8:00 a.m. – 5:00 p.m. Thursday, June 15, 2017 ACLS Part 2 IS Training Room 3 8:00 a.m. – 5:00 p.m. Monday, June 19, 2017 Hospital Orientation – Day 1 IS Training Room 3 7:30 a.m. – 4:00 p.m. Tuesday, June 20, 2017 Hospital Orientation – Day 2 IS Training Room 3 7:30 a.m. – 12:00 p.m. Wednesday, June 21, 2017 Medicine Orientation – Day 1 Mount Washington Conf. Center 8:00 a.m. – 4:00 p.m. Thursday, June 22, 2017 Medicine Orientation – Day 2 Mount Washington Conf. Center 8:00 a.m. – 4:00 p.m. Friday, June 30, 2017 New Resident Welcome Reception 4:00 p.m. – 6:00 p.m.
lower gastrointestinal bleeding. Chin J Paed 2008; 51:133-9. 18. Chen US, Chau RH, Liu VE, et al. Role of sigmoidoscopy in children in with persistent lower gastrointestinal bleeding. J Paed Child Health 2010; 47: 658-62. 19.Lovel GP. Malignant changes injuvenile colorectal polyps. Chin J PaedSurg 2009; 45: 127-32. 20. Morrison CI, Robbin MJ George RB et al. A prospective study of the changing pattern of juvenile colorectal polyps.Scand J Gastroenterol 2010; 43:54-60. 21. Gupta CV, Steele WN, Gorden AS et al. Revision of juvenile colorectal polyps in North America Chidren. EyptJ Gastroenterol 2009; 28: 62-7. 22. Francis GW, Masterton IH, Michael SS et al. Juvenile colorectal polyps: presentation and management. 23. Langers CI, Campell GJ, Rothe LR. Role of total colonoscopy in pediatric surgery.Int J Ped 2009; 14:503-8. 24. Earenst SW, Hardley GS, Sound WB et al. Gastrointestinal diseases. Jap J Surg 2010; 51: 203-6. 25. Mosby LK, Ruckley BN, Rogers VT et al. Proctitis versus proctosigmoiditis: an epidemiological study. Int J Dig Dis 2009; 51: 131-5. 26. Caperon EL, Martin AI, Vector DJ et al. Role of general stool exam in management of infectious diarrhea. Can J Inf Dis 2008; 42:201-8. Table 1 demonstrating aetiology of beelding per rectum % Number Aetiology 56.25 45 Rectal polyp 26.25 22 Infectious colitis 2.5 2 Non-specific colitis 2.5 2 Ulcerative colitis 3.75 3 Intussusception 2.5 2 Anal fissure 1.25 1 Meckels diverticulum
Results 30 diabetic type 2 patients were included in the study, and 30 non diabetic were included also as a control group .Table -2- shows the mean ages comparison and gender comparison between the two groups. The two groups were matched with regard to both age and gender. Table -3- illustrates the mean levels and standard deviations of thyroid function tests ( T3, T4, and TSH ) in the two groups . Table -4- shows the number and percentage of those who were found to have abnormal thyroid function tests in each group. 6 of the 30 diabetics i.e (20%) have abnormal thyroid function tests versus 1 of the 30 (3.33%) in the control group ( the difference is statistically significant with p value < 0.01) . Table -5- demonstrates the types of abnormal thyroid function tests in the diabetic group . Table 2 Gender and age distribution of diabetic type 2 and control subjects. Gender Number Mean age ± SD (years) Diabetic Total (30) Male Female 14 16 53.00 ± 11.90 Control Total (30) Male Female 15 15 52.00 ± 11.20 Table 3 Comparison between control and diabetic groups according to mean levels of thyroid function tests. Mean ± SD T3ng/ml T4 µg/dl TSH mIU/ml control 1.0434 ± 0.157 7.260 ± 1.336 1.384 ± 0.994 diabetic 1.090 ± 0.399 7.033 ± 0.970 1.737 ± 1.274 LSD Value P-value 0.083 NS 0.736 0.0454 * 0.036 0.187 * 0.0218 * (P<0.05), NS: Non-significant. Table 4 Number and percentage of those with abnormal thyroid function tests in both groups. Group Normal thyroid function Abnormal thyroid Function Total No. Chi-square value Diabetes No. 24 6 30 10.25 ** % 80.00 20.00 100 % Control No. 29 1 30
Mon 8.30 – 12.30 12.30 – 13.30 13.30 – 17.30 Academic work X-ray meeting / Journal Club General Rheumatology Clinic DCC DCC 1.0 0.25 1.0 Tues 8.30 – 12.30 13.30 – 17.30 Academic work Academic work 1.0 1.0 Wed 8.30 – 12.30 13.00 – 17.00 Academic work General Rheumatology Clinic (FU) DCC 1.0 1.0 Thur 08.30 – 12.30 13.00 – 14.00 14.00 – 17.00 Clinical admin / liaison with nurses Consultant Meeting PG Meeting/CPD/Audit/Clinical Governance DCC SPA SPA 1.0 0.25 0.75 Fri 09.00 – 11.00 11.00 – 13.00 13.00 – 15.00 Clinical Admin / Ward Round Academic SPA Academic work DCC SPA 0.5 0.5 0.5 Emergency Cover Flexible DCC 0.25 Total Direct Clinical Care 4 Supporting Professional Activity 1.5 Academic Activities 4.5 Programmed Activities 10 A review of duties will take place with the Clinical Director / Clinical Lead as part of the Job Plan process. Time will also be made available for the annual appraisal in line with the Trust and University appraisal policies. In addition to the out-patient commitment, you will take part in the rheumatology consultant on-call rota (currently 1:9). You will be required to cover for colleagues during periods of absence. You will have continuing responsibility for patients in your care and the proper functioning of the STH Rheumatology Department. Teaching You will contribute to the Undergraduate and Postgraduate teaching programmes of the Department of Infection & Immunity and Faculty of Medicine, Dentistry & Health
Date of Assessment 17.11.2017 Responsible Department Pharmacy Name of person completing assessment Amanda Cooper Job Director of Medicines Optimisation and Pharmacy Does the policy/function affect one group less or more favourably than another on the basis of : Yes/No Comments Age No Disability No Gender reassignment No Pregnancy and Maternity No Race No Sex No Religion or Belief No Sexual Orientation No Marriage and Civil Partnership No If the answer to all of the questions is NO, the EIA is complete. If YES, a full impact assessment is required: go on to stage 2, page 2 More Information can be found be following the link below Stage 2 – Full Impact Assessment What is the impact Level of Impact Mitigating Actions (what needs to be done to minimise / remove the impact) Responsible Officer
(19) The Permanent Secretary or the Council, as the case may be, or any person duly authorized thereto by the Permanent Secretary or the Council, as the case may be, must make a written inventory of all items collected as provided in subregulation (18) and the inventory must include - (a) the place, date and time of collection; (b) the name and personal details of the person from whom the items are collected; (c) the name and quantity of every item collected; and (d) the name of the person collecting the items. Application for registration of premises used for manufacturing of medicines and renewal of licence 35. (1) An application for the registration of a premises used for the manufacturing of medicines as contemplated in section 37A of the Act must be submitted to the Registrar in the form as set out in Annexure XXIX to these regulations. (2) An application form referred to in subregulation (1) must contain the information required therein. (3) A licence in respect of the registration of a premises used for the manufacturing of medicines must be issued in the form as set out in Annexure XXX to these regulations. (4) An application for the renewal of a licence in respect of the registration of a premises used for the manufacturing of medicines as contemplated in section 37D(2) of the Act must be made - (a) not later than three months before the expiry thereof, in the form as set out in Annexure XXXI to these regulations; and (b) must contain the information required therein. (5) A licence which has been renewed in respect of the registration of a premises used for the manufacturing of medicines must be issued in the form as set out in Annexure XXX to these regulations. Obtaining of pethidine or preparations or mixtures thereof and other scheduled substances by a registered nurse or a registered midwife 36. (1) A person registered as a nurse or a midwife in terms of the Nursing Act, 2004 (Act No. 8 of 2004), who intends to purchase, acquire or keep for administration in a midwifery case the scheduled substances set out in Annexure XXXII to these regulations, must apply in writing in the form as set out in Annexure XXXIII to these regulations therefore to the Permanent Secretary, stating in such application - (a) the type of nursing service for which the scheduled substances are required;
MONITORING COMPLIANCE WITH PROCEDURAL DOCUMENTS Minimum requirement to be monitored Lead Tool Frequency of Report of Compliance Reporting arrangements Lead(s) for acting on Recommendations Suppliers have the appropriate MHRA licence to supply medicines Pharmacy Operations Manager Website Annual Policy audit report to: Director of Medicines Management and Pharmacy Pharmacy Procurement Operations Manager Supplier electronic trading status reviewed for appropriateness Pharmacy Operations Manager Medecator & Powergate Annual Policy audit report to: Director of Medicines Management and Pharmacy Pharmacy Procurement Operations Manager Medication Errors related to issues identified in this policy Risk Pharmacist Datix Annual Policy audit report to: of Medicines Management and Pharmacy Risk Pharmacist Pharmacy Procurement Operations Manager Unlicensed Products Review Risk Pharmacist JAC Annual Policy audit report to: of Medicines Management and Pharmacy Clinical Pharmacy Leads This document will be monitored to ensure it is effective and to assure compliance.
APPENDIX 1: MEDICINE ERROR, INCIDENT AND DEFECT REPORTING SYSTEMS What systems are and when to use them When to Use Examples (not exhaustive list) Report Sent To Contact Information MHRA Defective Medicines Reporting Centre Suspected or actual product defect where patient safety clearly at risk. Guidance from the MHRA here Serious unexpected reaction. Severe, visible microbial or particulate contamination. Suspected counterfeit product MHRA Defective Medicines Reporting Centre Telephone: 020 3080 6574 (08:45 - 16:45 weekdays) 641532 for urgent calls outside of normal working hours, at weekends or on public holidays. dmrc@mhra.gsi.gov.uk Quality Assurance Defect Reporting Scheme Product defects which are quality assurance in nature, with no immediate severe risk to patient safety. Defects reported to the MHRA should also be copied to CMU for contract lines Empty blister in strip. Missing batch number or expiry date, particulate contamination. Defective unlicensed medicines should also be reported. Inform manufacturer. If necessary send sample to an NHS Regional QA service ProMS (Potential Risk of Medication Selection) Incidents where products have been selected or supplied incorrectly, where issues relating to packaging design and presentation are felt to be contributory factors. Selection of lookalike and sound-alike drugs. Manufacturer's packaging has poor differentiation between different products or strengths. Send to an NHS Regional QA Service As for minor defects above. In addition must be reported via the Trust Incident Reporting process via Datix CMU Issues relating to supply of medications purchased through CMU contracts. Change in manufacturer of product supplied. Financial and Relevant CMU buyer for Trust concerned. See contact details for individual buyers.
RENAL DISEAS OVER 12 1 TABLET EVERY 4-6 HOURS HEADACHE, DRY MOTUH. PIRITON SYRUP ALLERGY AS ABOVE 2-6 YEARS: 2.5 MLS EVERY 4-6 HOURS (MAX DOSE = 2X2.5MLS IN ANY 24 HOUR PERIOD). 6-12 YRS: 5MLS EVERY 4-6 HOURS (MAX DOSE 6X5MLS IN ANY 24 HOUR PERIOD). AS ABOVE MEDICATION INDICATION CONTRAINDICATIONS DOSE SIDE EFFECTS PRITON SYRUP (CONT) ALLERGY AS ABOVE CHILDREN OVER 12: 10MLS EVERY 4-6 HOURS (MAX=12X10ML DOSES IN 24 HOURS) AS ABOVE IBUPROFEN 200MG TABLETS PAIN AND FEVER PEPTIC ULCER, ASTHMA, RENAL OR CARDIAC IMPAIRMENT, HEART FAILURE, HYPERTENSION, GI DISEASE, COAGULATION DEFECTS ADULTS AND CHILDREN OVER 12 YEARS EVERY 4-6 HOURS AS REQUIRED GI UPSET, HAEMORRHAGE, RASH, THROMBOCYTOPENIA IBUPROFEN SYRUP 100MG/5MLS PAIN FEVER AS ABOVE 4 – 7 YEARS:150MG THREE TIMES A DAY 7-12 YEARS 200MG THREE TIMES A DAY. AS ABOVE PAEDIATRIC SIMPLE LINCTUS RELIEF OF COUGH DO NOT USE IF ALLERGIC TO INGREDIENTS 6-12 YEARS GIE 2X5ML SPOONFULL EVERY 4 HOURS UP TO 4 TIMES A DAY NOT EXPECTED THROAT LOZENGERS RELIEF OF COUGH/SORE THROAT DIABETES 1 LOZENGE WHEN REQUIRED NOT EXPECTED JUNGLE FORMULA ALL STINGS NOT TO BE USED ON BROKEN SKIN OR NEAR NOSE OR MOUTH SPRAY FOR 2-3 SECONDS NOT EXPECTED SAVLON ANTISEPTIC SPRAY MINOR WOUNDS AVOID CONTACT WITH EYES AND EARS SRAY ONTO AFFECTED AREA TO FLOOD WOUND NOT EXPECTED TCP MOUTH ULCERS, CUTS, BITES ALLERGIC SKIN CONDITION DAB LIGHTLY NOT EXPECTED DIORALYTE DIARRHEOA DO NOT USE IF ALLERGIC TO INGEDIENTS ONE SACHET AFTER EVRY LOOSE BOWEL MOTION NOT EXPECTED OLBUS OIL CONGESTION INHALE VAPOURS NOT EXPECTED ARNICA CREAM FOR MILD BRUISING DO NOT USE IF ALLERGIC TO INGEDIENTS APPLY TOPICALLY PRN NOT EXPECTED MAGNESIUM SULPHATE BOILS DO NOT USE IF ALLERGIC TO INGREDIENTS APPLY TO AFFECTED AREA NOT EXPECTED VASELINE DRY SKIN CONDITIONS DO NOT USE IF ALLERGIC TO INGREDIENTS APPLY TO AFFECTED AREA NOT EXPECTED E45 CREAM DRY SKIN CONDITIONS DO NOT USE IF ALLERGIC TO INGREDIENTS APPLY TO AFFECTED AREA NOT EXPECTED
BONJELLA TEETHING GELS GUM PAIN DO NOT USE IF ALLERGIC TO INGREDIENTS APPLY TO AFFECTED AREA NOT EXPECTED CALAMINE LOTION MINOR SKIN COMPLAINTS AND ITCHING AVOID EYES/MOUTH/NOE/GENITAL AREA APPLY WITH COTTON WOOL AS REQUIRED NOT EXPECTED PEPPERMINT WATER RELIEF OF INDIGESTION DO NOT USE IF ALLERGIC TO INGREDIENTS DILUTE WITH H20 NOT EXPECTED KWELLS PREVENTION OF MOTION SICKNESS DO NOT USE IF ALLERGIC OR HISTORY OF GASTRIC PROBLEMS ADMINISTER 20-30 M INS PRIOR TO TRAVEL CHILDREN 4-10 GIVE ½ TO 1 TABLET EVERY 4 HOURS. CHILDREN OVER 10 GIVE 1-2 TABLETS EVERY 6 HOURS DRY DIZZYNESS, DROWSINESS INCRESED TEMP, BLURRED VISION, DILATED PUPILS FULL MARKS TREATMENT OF HEADLICE DO NOT USE IF ALLERGIC TO INGREDIENTS APPLY TO WET HAIR NOT EXPECTED
My transformed thoughts: reading this book, I am wondering how one becomes an Elder and where they can be reached. Are there fewer Elders all the time? Are there different types of Elders? I am also curious to know how these traditions have changed over the past decades. It would be interesting to compare a naming ceremony that would have been done to a naming ceremony that would be conducted today. Highly recommend Recommend for additional reading Any additional thoughts: ISBN: 978-9780808-3-9 Review/Critique Reviewer’s Name: Cheryl Kruchak Date: September 24th Aliki. (1976). Corn is maize: The gift of the Indians. New York, NY: Harper Collins. Why I chose this book: I chose this book because it appropriate for earlier years classrooms. It uses one central topic, corn, to tell a story that incorporates many different Aboriginal traditions. An entire science unit could be based on this one book. It has many descriptive pictures for students to see. The writing is child-friendly and it is centered around a topic that students can relate to.
References Searched: (e.g. Stockley’s Drug Interactions, 9th edition Appraisal of findings from resources: Summary (answer for enquirer): Time taken: <15min, 15-30min, 30-60min, 1-4hr, 4-8hr, >8hr Date of response and route of response:
Policy of grafting the new compositions of enunciation: Medicine and Art. Dating land. Heidegger Martin. 1952. Transl. 1973 “El Origen de la Obra de Arte” Chap. “Holderlin y la Esencia de la Poesía”. Printed by “Editorial Fondo de Cultura Económica” Deleuze Gilles –Guattari Felix. 1980. Transl. 1988. “Mil Mesetas”. Chap. “Introducción: Rizoma. Page 20. Printed by “Pre Textos” Ibid Page 13 Ibid Page 13 Ibid Page 17 Deleuze Gilles. 1968. Transl. 1988. “Diferencia y Repetición. Chap. “La diferencia en sí”. Printed by “Jucar . Universidad” Foucault Michel. 1966. Transl. 1984 “Las Palabras y las Cosas” Chap. “El Cogito y lo Impensado”. Page 313. Printed by “Siglo XXI! “What is Philosophy?” I, María Ester Valdés, sworn translator, attest that this is a true complete translation of a document which I have seen. Rosario, 18th June 2013. Yo, María Ester Valdés, inscripta en la matrícula Nº 958/02, 2º Circunscripción, doy fe de que la presente es traducción fiel y completa de un original que tuve ante mí. Junio 18,2013. Dejo constancia que la traducción se presente en este formato a solicitud de la interesada.
an effective army sewers An underground system for removing human waste Theory of Opposites The treatment of Humoural causes of disease. Rebalancing by eating or climate from the opposite eg hot, red food to treat excess phlegm. (I) In a Nutshell: Overview of Medicine 1250-1500 Content overview Focus 1 Ideas about the cause of disease and illness and the miasma theory; the continuing influence in England of and . Focus 2 Approaches to prevention and treatment : religious actions, bloodletting and purging, purifying the air, and the use of remedies. . The role of the, and in treatment and care provided within the community and in hospitals, c1250–1500. Focus 3 Case study approaches to treatment and attempts to prevent its spread. (II) Causes and Analysis of developments: Focus : Factors of change and continuity in Medical developments 1250-1500. Activity 1 a copy in your book and highlight the key points. Role of Individuals The teachings of individuals like Hippocrates and Galen continued to be preserved by the Church in the years after the Roman Empire collapsed. However there were few significant individuals within the middle ages to really promote new approaches to the causes and treatments of illness and disease. Old After the Romans left Britain in 383 AD the Church preserved old ideas but also bound them up with ideas of God. There were little progress in Medicine by 1500 in terms of new ideas. Traditional cures and remedies continued to be important, and prayer was encouraged. Role of Government After the fragmented government for the early middle ages, there was greater centralised power and control within the period 1250-1500. Hoever, warfare was the main concern of King and government in this period, rather than medical developments. Local town authorities had some influence in terms of public health regulations FACTORS OF
p30 1 Natural Treatments 2 Keeping Healthy 3 Four Humours/Theory of the Opposites Activity 2 Using DBL SHP Medicine text p38-41 make notes on Medieval healers, their experience and methods. Who could you get Medical help from in Medieval Britain? What experience did they have? How would they treat you? 1 p38-39, p43 Experience 1 2 3 2 In hospitals. Gods and their priests, and care homes. p40 Experience 1 2 3 3 Trained doctors disappeared! Local healers p38 Experience 1 2 3 4 Women p41 Experience 1 2 3 Activity 3 DBL SHP Medicine text p44-45 make notes on Medieval healers, their experience and methods.
CONSOLATO GENERALE D’ITALIA TORONTO CONSULATE –APPROVED PHYSICIAN THE FOLLOWING IS THE CONSULATE –APPROVED PHYSICIAN WHO IS AUTHORIZED TO ISSUE THE MEDICAL CERTIFICATE REQUIRED TO RENEW THE ITALIAN DRIVER’S LICENCE NOME INDIRIZZO CITTA’ CODICE POSTALE TELEFONO VARLESE F. 55 Avenue Rd Suite 2880 – Baycrest Hospital (3560 Bathurst Street) TORONTO MSR 3L2 M6A 2X8 (416) (416) This physician can issue various certificates, such as those requested by our Consulate, other public administrations or private parties requesting medical assessments, or for the renewal of driver’s licences..